| Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01. JJ Knox, EM Jaffee, GM O'Kane, D King, D Laheru, KH Yu, K Perez, ... Journal of Clinical Oncology 42 (17_suppl), LBA4004-LBA4004, 2024 | | 2024 |
| FEASIBILITY OF ENDOSCOPIC ULTRASOUND-GUIDED TISSUE ACQUISITION FOR NEXT-GENERATION SEQUENCING IN PANCREATIC CANCER PATIENTS SE Lee, D Kim, M Schattner, V Rolston, E Vakiani, C Sigel, E O'Reilly, ... Gastrointestinal Endoscopy 99 (6), AB858-AB859, 2024 | | 2024 |
| Adjuvant mFOLFIRINOX (mFFX) for resected pancreatic cancer (PC): Long term clinical and genomic outcomes. F Keane, D Moss, CA O'Connor, M Perry, JF Chou, F Crowley, P Saxena, ... Journal of Clinical Oncology 42 (16_suppl), 4170-4170, 2024 | | 2024 |
| Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses. CA O'Connor, E Harrold, YT Lin, HS Walch, A Gazzo, SR Kane, F Keane, ... Journal of Clinical Oncology 42 (16_suppl), 4144-4144, 2024 | | 2024 |
| Advances in Systemic Therapy in Pancreatic Cancer HY Kenneth Hematology/Oncology Clinics 38 (3), 617-627, 2024 | | 2024 |
| Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication I Singh, JF Chou, M Capanu, J Park, HY Kenneth, AM Varghese, W Park, ... Pancreatology, 2024 | | 2024 |
| Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease F Keane, JF Chou, H Walch, J Schoenfeld, A Singhal, D Cowzer, ... JNCI: Journal of the National Cancer Institute, djae095, 2024 | | 2024 |
| Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery EC Dee, VC Ng, EM O’Reilly, AC Wei, SM Lobaugh, AM Varghese, ... Journal of Clinical Medicine 13 (9), 2631, 2024 | | 2024 |
| Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across … AM Varghese, MA Perry, D Muldoon, S Nandakumar, A Erakky, B Nguyen, ... Cancer Research 84 (2_Supplement), C074-C074, 2024 | | 2024 |
| Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC) E Harrold, CA O'Connor, D Lin, A Gazzo, H Walch, M Ranganathan, ... Cancer Research 84 (2_Supplement), B042-B042, 2024 | | 2024 |
| Abstract C104: Dual primary pancreas cancers–Related or independent lesions? JD Schoenfeld, H Sahan-Ozkan, N Bilani, MI D'Angelica, WR Jarnagin, ... Cancer Research 84 (2_Supplement), C104-C104, 2024 | | 2024 |
| Abstract B045: Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer W Park, S Umeda, C O'Connor, H Zhang, R Sharma, A Richards, Y Zhu, ... Cancer Research 84 (2_Supplement), B045-B045, 2024 | | 2024 |
| Clinico-genomic characterization of N= 2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages AM Varghese, MA Perry, D Muldoon, S Nandakumar, A Erakky, B Nguyen, ... CANCER RESEARCH 84 (2), 2024 | | 2024 |
| A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer. R Tuli, F Keane, JD Schoenfeld, C O'Connor, C White, JF Chou, ... Journal of Clinical Oncology 41 (16_suppl), 4164-4164, 2023 | 2 | 2023 |
| Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination … W Park, C O'Connor, JF Chou, C Schwartz, AM Varghese, M Larsen, ... Journal of Clinical Oncology 41 (16_suppl), 4140-4140, 2023 | 5 | 2023 |
| Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC). F Keane, L Saadat, C O'Connor, JF Chou, AR Brannon, D Cowzer, ... Journal of Clinical Oncology 41 (16_suppl), 4154-4154, 2023 | | 2023 |
| Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC) W Park, C O'Connor, S Umeda, R Sharma, Y Zhu, ER Karnoub, ... Cancer Research 83 (7_Supplement), 6421-6421, 2023 | | 2023 |
| Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma KH Yu, P Cockrum, A Surinach, N Lamarre, S Wang, EM O'Reilly Cancer Medicine 12 (8), 9496-9505, 2023 | 3 | 2023 |
| A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC). F Keane, JD Schoenfeld, F Crowley, CA O'Connor, C White, C Schwartz, ... Journal of Clinical Oncology 41 (4_suppl), 725-725, 2023 | 1 | 2023 |
| The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation. KH Yu, CD Weekes, YBA Chen, JA Glazier, A Glazier, P Dahi, S Giralt, ... Journal of Clinical Oncology 41 (4_suppl), TPS774-TPS774, 2023 | | 2023 |
Eileen M. O'ReillyMemorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
